Navigation Links
CC Cages

ProductsCC Cages
Company Scient'x
Item CC Cages
Features 
  • Stabilisation ensured through neutralisation of the axial compression forces and through conservation of the interbody space.
  • The shape of CC cages ensures durability of the interbody space preservation.
  • Horizontal and vertical stabilisations favour early rehabilitation.
  • CC cages are anatomically designed to fit the intervertebral disc space.
  • The upper and lower convex shaped surfaces are notched to achieve stabilisation of the implants within the vertebral end plates.
  • CC cages offer an optimal grafting surface to enhance the quality of the ar throdesis.
    • Description The CC cages are designed to facilitate an arthrodesis, either by an anterior or posterior approach. These are interbody cages allowing radicular compression by restoring the height of the interve rtebral space and of the foramina, which in turn enhances osteogenesis.The CC cages are particularly indicated for major lumbar instabilities. CC cages are made of PEEK polymer (poly (ether ether ketone)), a biocompatible material which allows a per fect visualisation of the osteogenesis by radiolucency. Two metallic markers facilitate orientation and location of the implant on imaging. This material presents a modulus of elasticity (Youngs modulus) close to that of cortical bone,improving the biomechanical interface. CC cages fulfil the requirement for the stabilisation and safety.
    Info Scient'x
    Customer Service: (407) 571-2550
    Web site: http://www.scientx.com/

    Related medicine products :

    1. DGH Pachette 3 Ultrasonic Pachymeter
    Lumicon 48 mm red filter....
    Heavy duty, all purpose illuminator available in blue and green. Unique Clip Switch automatically turns off when returned to pocket. Pre-focused lens tip Heine XHL Halogen bulb for bright, concentra...
    ... A child-friendly vision test ... takes just seconds. Welch ... first objective, accurate vision ... early detection of refractive ...
    ... is a black and white ... by people who have visual ... control selector, the Classic can ... black text on a white ...
    Medicine Products:
    (Date:6/19/2013)... According to Transparency Market Research “Endoscopy ... Analysis and Forecast, 2011 – 2017,” the global endoscopy ... year 2011 and is expected to reach USD 10.8 ... from 2011 to 2017. Flexible endoscopes formed the largest ... 2,201 million for the year 2011. , Related Report ...
    (Date:6/19/2013)... Ore. For years, Alzheimer,s researchers have focused on ... with Alzheimer,s and may contribute to the disease: plaques ... another protein, called tau. , But for the first ... the two proteins independently, but at the interaction of ... brain tissue of post-mortem Alzheimer,s patients and in mouse ...
    (Date:6/19/2013)... 19, 2013 AquaPrint Solutions in Thomson, IL ... Grub with a newly-designed Harley Davidson motorcycle gas tank. A ... Solutions with an idea of taking a split tank motorcycle ... and transforming it into a work of art. , ... Grub several toilet seats that had been dipped in a ...
    (Date:6/19/2013)... 19, 2013 The Cancer Support Community ... of cancer care for the whole patient with the ... Cancer Support Community. This inaugural event, held at the ... MD., Ph.D., recognition of Congress members who have made ... of patients and families currently engaged in the cancer ...
    (Date:6/19/2013)... (PRWEB) June 19, 2013 North ... PT continuing education course with an online ... therapy assistants and occupational therapists. , ... course supplemented by an online continuing education ... level algorithmic problem solving skills needed to evaluate ...
    Breaking Medicine News(10 mins):Health News:Endoscopy Devices Market Will Reach USD 10.8 Billion in 2017 : Transparency Market Research 2Health News:Endoscopy Devices Market Will Reach USD 10.8 Billion in 2017 : Transparency Market Research 3Health News:New Alzheimer's research suggests possible cause: The interaction of proteins in the brain 2Health News:AquaPrint Solutions Transforms Harley Davidson Gas Tank into a Work Of Art for Poopy’s Pub & Grub 2Health News:Keeping the Promise of Cancer Care for the Whole Patient 2Health News:Keeping the Promise of Cancer Care for the Whole Patient 3Health News:New Evidence Based Information on Treatment for Over 8 Million People in the U.S. Affected With Disorders of the Vestibular System 2
    ... Nursing (NYUCN) received a four-year, $ 2.8M grant from ... and Infectious Diseases (NIH/NIAID) to study "Combination HIV ... is a collaboration between NYUCN, the University of Nairobi, ... Principal Investigator Ann Kurth notes that HIV ...
    ... FRIDAY, Oct. 28 (HealthDay News) -- Surgery to remove ... as a thyroidectomy, appears to reduce snoring and other ... study. Researchers compared symptoms in patients with obstructive ... a thyroidectomy. Symptoms of obstructive sleep apnea include snoring, ...
    ... -- In 2008, as part of a larger initiative aimed ... reimbursing for the treatment of injuries related to in-hospital falls. ... could have an unintended negative consequence. In trying to ... that hospitals might discourage patients from moving about at all. ...
    ... against a whole range of bacterial pathogens, have been ... drugs to treat viral diseases, on the other hand, ... led by Dr. Albrecht von Brunn of LMU Munich ... have identified a compound that inhibits the replication of ...
    ... than 1.5 billion overweight adults, including 400 million who are obese. ... women and 60 per cent of men are either overweight or ... weight loss, more than 80 per cent of obese dieters fail ... overweight or obese adults, with a BMI of between 27 and ...
    ... Trying to avoid eating the entire bag of candy bars ... that you won,t have the willpower to resist midnight raids ... be scary for your diet, according to Kara Smith, special ... several tips on how to limit empty Halloween calories, including: ...
    Cached Medicine News:Health News:NYUCN receives $2.8 million NIH/NIAID grant to study combination HIV prevention for Kenyan youth 2Health News:Thyroid Surgery Linked to Improved Sleep Apnea Symptoms 2Health News:Study finds no link between elderly patient activity and hospital falls 2Health News:Novel strategy stymies SARS et al. 2Health News:Novel strategy stymies SARS et al. 3Health News:Obese people regain weight after dieting due to hormones 2
    (Date:6/19/2013)... , June 19, 2013   Nektar Therapeutics (Nasdaq: ... a human abuse liability (HAL) study for NKTR-181, ... entry into the brain.  This slow rate of entry is ... abuse of and addiction to current opioid analgesics. 1 ... was rated similar to placebo in "drug liking" and "feeling ...
    (Date:6/19/2013)... Calif. , June 19, 2013 BD Biosciences, ... BDX ), a leading global medical technology company, today ... Analyzer , the latest in its line of high-performance research ... Analyzer delivers high-performance multicolor analysis with the most compact footprint ... 73.7 cm) and a height of 30" (76.2 cm). Recognizing ...
    (Date:6/19/2013)... , June 19, 2013 NeuroDerm, ... study in volunteers, and preliminary results from a phase ... presented at the 2013 International Congress of Parkinson,s Disease ... drug formula under development for continuous administration through a ... plasma concentrations. ND0612 has been shown in ...
    Breaking Medicine Technology:Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 2Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 3Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 4Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 5Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 6Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 7Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 8Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 9New BD Biosciences Flow Cytometry Cell Analyzer Enables Complex Multicolor Experiments in Disease Research 2NeuroDerm Announces Presentation of Data from Studies Evaluating ND0612, an Investigational Levodopa Continuous Administration Drug, in Healthy Volunteers and in Patients with Advanced Parkinson's Disease 2NeuroDerm Announces Presentation of Data from Studies Evaluating ND0612, an Investigational Levodopa Continuous Administration Drug, in Healthy Volunteers and in Patients with Advanced Parkinson's Disease 3NeuroDerm Announces Presentation of Data from Studies Evaluating ND0612, an Investigational Levodopa Continuous Administration Drug, in Healthy Volunteers and in Patients with Advanced Parkinson's Disease 4NeuroDerm Announces Presentation of Data from Studies Evaluating ND0612, an Investigational Levodopa Continuous Administration Drug, in Healthy Volunteers and in Patients with Advanced Parkinson's Disease 5NeuroDerm Announces Presentation of Data from Studies Evaluating ND0612, an Investigational Levodopa Continuous Administration Drug, in Healthy Volunteers and in Patients with Advanced Parkinson's Disease 6